Equities research analysts expect Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) to announce earnings per share of ($1.14) for the current quarter, Zacks reports. Zero analysts have made estimates for Zentalis Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.93) and the lowest estimate coming in at ($1.29). Zentalis Pharmaceuticals reported earnings per share of ($0.78) in the same quarter last year, which would indicate a negative year-over-year growth rate of 46.2%. The business is expected to announce its next earnings results on Thursday, August 12th.
On average, analysts expect that Zentalis Pharmaceuticals will report full year earnings of ($4.61) per share for the current fiscal year, with EPS estimates ranging from ($5.41) to ($3.70). For the next financial year, analysts forecast that the business will report earnings of ($4.75) per share, with EPS estimates ranging from ($5.74) to ($3.22). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Zentalis Pharmaceuticals.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Monday, May 17th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.27).
Shares of NASDAQ:ZNTL traded down $0.84 during midday trading on Friday, hitting $49.75. 485 shares of the company’s stock traded hands, compared to its average volume of 359,127. The firm has a fifty day moving average price of $52.91. Zentalis Pharmaceuticals has a twelve month low of $25.41 and a twelve month high of $62.79.
In other Zentalis Pharmaceuticals news, CEO Anthony Y. Sun sold 25,045 shares of the business’s stock in a transaction dated Tuesday, July 6th. The shares were sold at an average price of $46.90, for a total transaction of $1,174,610.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Anthony Y. Sun sold 26,794 shares of the company’s stock in a transaction that occurred on Monday, May 3rd. The stock was sold at an average price of $59.32, for a total transaction of $1,589,420.08. Following the completion of the sale, the chief executive officer now directly owns 1,474,161 shares of the company’s stock, valued at $87,447,230.52. The disclosure for this sale can be found here. Insiders have sold a total of 206,032 shares of company stock valued at $10,798,251 over the last three months. 21.00% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the company. Wells Fargo & Company MN lifted its stake in shares of Zentalis Pharmaceuticals by 99.6% in the 4th quarter. Wells Fargo & Company MN now owns 16,865 shares of the company’s stock worth $876,000 after acquiring an additional 8,415 shares during the period. Northern Trust Corp lifted its stake in shares of Zentalis Pharmaceuticals by 0.3% in the 1st quarter. Northern Trust Corp now owns 283,323 shares of the company’s stock worth $12,293,000 after acquiring an additional 881 shares during the period. UBS Asset Management Americas Inc. lifted its stake in shares of Zentalis Pharmaceuticals by 53.0% in the 1st quarter. UBS Asset Management Americas Inc. now owns 17,600 shares of the company’s stock worth $764,000 after acquiring an additional 6,100 shares during the period. Silverarc Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $519,000. Finally, Virtu Financial LLC bought a new stake in Zentalis Pharmaceuticals during the fourth quarter worth approximately $371,000. 87.82% of the stock is owned by institutional investors.
Zentalis Pharmaceuticals Company Profile
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer.
Recommended Story: How much can an individual set aside as a catch-up contribution?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.